Tenosynovial Giant Cell Tumors Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
In the fourth episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent trial data and evolving therapies for treatment of Ewing sarcoma.
View More
Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent data comparing the American Standard versus European Standard for treatment of Ewing sarcoma.
View More
True or False: Radiotherapy is no longer a primary therapy option in most tertiary tumor centers, while surgical resection, either open or arthroscopic, is.
View More
Claire Verschraegen, MD, discusses a study that examined the knowledge, attitudes, and behavior of patients and providers with regards to the safety and use of pexidartinib.
View More
Claire Verschraegen, MD, comments on a real-world study examining the treatment and quality-of-life of patients with diffuse-type TGCT.
View More
In this follow-up episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, continue to discuss how the diagnosis of and treatment landscape for TGCT has evolved in recent years.
View More
In this inaugural episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss the challenges of treating TGCTs and how the treatment landscape has evolved.
View More
Dr van de Sande shares how TGCT therapy has evolved in the past 15 years, and walks through outcomes for surgery, RT, and pharmacotherapy.
View More
Robert Maki, MD, PhD, comments on a study in which TGCTs were found to be characterized by variable alterations.
View More
Stay in the know.
OncNet Newsletter